ArticleAnnals of medicine2026

Efficacy and metabolic outcomes of switching from an INSTI-based triple-drug regimen to dolutegravir/lamivudine in treatment-experienced HIV-1-infected patients: a 48-week real-world study.

Wei Zhang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.